<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-132356</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Is it safe to perform joint infiltrations or aspirations in patients anticoagulated with acenocoumarol?</dc:title>
<dc:description xml:lang="en">The purpose of this study is to determine the rate of bleeding complications in patient's anticoagulated with acenocoumarol according to the international normalized ratio (INR) coagulation index. A cross-sectional study was performed with 901 charts of patients who underwent arthrocentesis or joint infiltration between 2009 and 2013; the charts were grouped on the basis of having an INR higher or lower than 2.0 (268 and 633, respectively). Comparisons were performed in terms of rates of early or late bleeding complications. A 0.37% rate of early bleeding complications (&lt;24 h) was observed in the group of patients with INR&lt;2 and 0.99% in the group of patients with INR&amp;#8805;2 (P=.47). Only one case of late complication was presented by bleeding between 24 h and 30 days, in the group of patients with INR&amp;#8805;2. We conclude that oral anticoagulation with acenocoumarol at therapeutic doses does not increase the risk of bleeding joint punctures (AU)</dc:description>
<dc:creator>Guillen Astete, Carlos</dc:creator>
<dc:creator>Boteanua, Alina</dc:creator>
<dc:creator>Garcia Montes, Nuria</dc:creator>
<dc:creator>Zea Mendoza, Antonio</dc:creator>
<dc:creator>Carballo Carmano, César</dc:creator>
<dc:creator>Medina Quiñones, Carmen</dc:creator>
<dc:creator>Roldan Moll, Fernando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El propósito del presente estudio es determinar la tasa de complicaciones por sangrado en pacientes anticoagulados con acenocumarol en función del índice normalizado internacional (INR) de coagulación. Se realizó un estudio retrospectivo con 901 registros de pacientes a quienes se les practicó una artrocentesis o infiltración articular entre 2009 y 2013, se agruparon los registros en función de tener un INR superior o inferior a 2,0 (268 y 633 registros, respectivamente) y se compararon las tasas de complicaciones por sangrado. Se observó una tasa de 0,37% de complicaciones por sangrado tempranas (&lt; 24 h) en el grupo de pacientes con INR &lt; 2 y una tasa de 0,99% en el grupo de pacientes con INR &amp;#8805; 2 (p = 0,47). Solo se presentó un caso de complicación por sangrado tardío, entre 24 h y 30 días, en el grupo de pacientes con INR &amp;#8805; 2. Concluimos que la anticoagulación oral a dosis terapéutica con acenocumarol no incrementa el riesgo de sangrado por punciones articulares (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);11(1): 9-11, ene.-feb. 2015. tab</dc:source>
<dc:identifier>ibc-132356</dc:identifier>
<dc:title xml:lang="es">Es seguro realizar infiltraciones o aspiraciones articulares en pacientes anticoagulados con acenocumarol?</dc:title>
<dc:subject>^d1804^s22021</dc:subject>
<dc:subject>^d1805^s22057</dc:subject>
<dc:subject>^d1805^s22054</dc:subject>
<dc:subject>^d6622^s22012</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d6622^s22057</dc:subject>
<dc:subject>^d7444^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6622^s22036</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d78^s22073</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201502</dc:date>
</metadata>
</record>
</ibecs-document>
